FDA 483 - Huvepharma Inc. - August 10, 2021

Huvepharma Inc, a veterinary drug manufacturer in Saint Louis, MO, received a Form 483 with three observations during an FDA inspection. The firm was cited for deficiencies in controlling drug product labeling, failing to follow pest control procedures, and not adequately verifying testing methods. These issues highlight concerns with quality control and adherence to established operational protocols.